Table 6 Antibiotic sensitivity of Listeria monocytogenes strains obtained from human (n=11)
| Antibiotics | Strains obtained from human | Sensitivity of the isolates (n, %)1) |
| SMFM-CI-1 | SMFM-CI-2 | SMFM-CI-3 | SMFM-CI-4 | SMFM-CI-5 | SMFM-CI-6 | SMFM-CI-7 | SMFM-CI-8 | SMFM-CI-9 | SMFM-CI-10 | SMFM-CI-11 | Susceptible | Intermediate | Resistant |
| Gentamycin | S | S | S | S | S | S | S | S | S | S | S | 11(100) | | |
| Bacitracin | S | R | S | R | S | S | R | S | S | S | S | 8(72.7) | | 3(27.3) |
| Penicillin G | R | R | R | R | R | R | R | R | R | R | R | | | 11(100) |
| Tetracycline | S | S | R | S | R | R | S | S | S | S | S | 8(72.7) | | 3(27.3) |
| Spectinomycin | S | S | S | S | S | S | S | S | S | S | S | 11(100) | | |
| Kanamycin | S | S | S | S | S | S | S | S | S | S | S | 11(100) | | |
| Erythromycin | S | I | S | R | S | S | R | S | S | S | S | 8(72.7) | 1(9.1) | 2(18.2) |
| Tigecycline | S | S | S | S | S | S | S | S | S | S | S | 11(100) | | |
| Ampicillin | S | R | S | R | S | S | R | S | S | S | S | 8(72.7) | | 3(27.3) |
| Streptomycin | I | R | R | R | R | R | R | S | R | I | I | 1(9.1) | 3(27.3) | 7(63.6) |
| Chloramphenicol | S | S | S | S | S | S | S | S | S | S | S | 11(100) | | |
| Rifampicin | S | R | S | R | S | S | R | S | S | S | S | 8(72.7) | | 3(27.3) |
| Susceptible(n, %) | 10(83.3) | 6(50) | 9(75) | 6(50) | 9(75) | 9(75) | 6(50) | 11(91.7) | 10(83.3) | 10(83.3) | 10(83.3) | | | |
| Intermediate(n, %) | 1(8.3) | 1(8.3) | | | | | | | | 1(8.3) | 1(8.3) | | | | |
| Resistant(n, %) | 1(8.3) | 5(41.7) | 3(25) | 6(50) | 3(25) | 3(25) | 6(50) | 1(8.3) | 2(16.7) | 1(8.3) | 1(8.3) | | | | |
1) According to CLSI guidelines using the breakpoints of Staphylococcus species resistance because no resistance criteria exist for Listeria susceptibility testing in the CLSI guidelines (Byrne et al., 2016).